Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Glioblastoma 203Brain Neoplasms 94Gliosarcoma 93Glioma 88Central Nervous System Neoplasms 78Astrocytoma 66Oligodendroglioma 45Melanoma 37Medulloblastoma 18Neuroblastoma 17Neoplasm Metastasis 14Ependymoma 13Neoplasms 10Choroid Plexus Neoplasms 10Sarcoma 9Recurrence 9Optic Nerve Glioma 9Familial ependymoma 9Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Lung Neoplasms 8Spinal Cord Neoplasms 7Breast Neoplasms 7Uveal Melanoma 6Sarcoma, Ewing 6Rhabdoid Tumor 6Pinealoma 6Neuroectodermal Tumors, Primitive 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5

Interventions

Cytarabine 9fludarabine 5Imatinib Mesylate 5thymoglobulin 3fludarabine phosphate 3Tacrolimus 3Sirolimus 3Methotrexate 3Cyclophosphamide 3Busulfan 3Azacitidine 3zosuquidar trihydrochloride 2venetoclax 2ponatinib 2nilotinib 2enasidenib 2bosutinib 2RO6839921 2Mycophenolic Acid 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Behavior Therapy 2Antilymphocyte Serum 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1quizartinib 1plerixafor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid × Temozolomide × Clear all
NCT00611247 2018-06-15

Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Completed
42 enrolled 8 charts
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡